Sort
48,018 grants matching “immunotherapy”
Mechanisms for post-COVID pituitary damage
$391,475Takako Araki · University Of Minnesota · R01 · FY2023 · DK
Preclinical Study of Peptide Based Human Tumor Vaccines
$391,471Victor H. Engelhard · University Of Virginia · R01 · FY2007 · CA
Synergy of the innate and acquired immune responses in tumor immunology
$391,469Randolph J. Noelle · Dartmouth College · R01 · FY2009 · CA
Proj 2 - Lymphatic system as a conduit for age-related defective proteostasis in AD
$391,440Laura Santambrogio · Albert Einstein College Of Medicine · P01 · FY2021 · AG
Proj 2 - Lymphatic system as a conduit for age-related defective proteostasis in AD
$391,440Laura Santambrogio · Albert Einstein College Of Medicine · P01 · FY2022 · AG
Proj 2 - Lymphatic system as a conduit for age-related defective proteostasis in AD
$391,440Laura Santambrogio · Albert Einstein College Of Medicine · P01 · FY2023 · AG
Proj 2 - Lymphatic system as a conduit for age-related defective proteostasis in AD
$391,438Laura Santambrogio · Albert Einstein College Of Medicine · P01 · FY2024 · AG
Identification of T Cell-Defined Antigens in Ovarian Cancer
$391,435Cassian Yee · Fred Hutchinson Cancer Research Center · R33 · FY2008 · CA
Leukemia Immunotherapy After Allogeneic Transplant
$391,430University Of Rochester · R01 · FY2005 · CA
Development of Highly Multiplex Antigen Specificity Assays
$391,426Harry Benjamin Larman · Johns Hopkins University · U24 · FY2017 · AI
Neoantigen-specific Adoptive T Cell Therapy for Glioblastoma, IND-BB-13135, protocol submitted 04/25/2020
$391,420Gary W. Wood · Tvax Biomedical, Inc. · R01 · FY2025 · FD
Preclinical Study of Peptide Based Human Tumor Vaccines
$391,420Victor H. Engelhard · University Of Virginia · R01 · FY2006 · CA
IDO2 Targeting in Pancreatic Cancer
$391,418George C Prendergast · Lankenau Institute For Medical Research · R01 · FY2017 · CA
IDO2 Targeting in Pancreatic Cancer
$391,418George C Prendergast · Lankenau Institute For Medical Research · R01 · FY2018 · CA
IDO2 Targeting in Pancreatic Cancer
$391,418George C Prendergast · Lankenau Institute For Medical Research · R01 · FY2016 · CA
ST8Sia6 expression on tumors inhibits the immune response
$391,416Virginia Smith Shapiro · Mayo Clinic Rochester · R01 · FY2022 · CA
ST8Sia6 expression on tumors inhibits the immune response
$391,416Virginia Smith Shapiro · Mayo Clinic Rochester · R01 · FY2023 · CA
Core A: Administrative and Clinical Translational Core
$391,372Carl H. June · University Of Pennsylvania · P01 · FY2025 · CA
Targeting the colchicine site in tubulin for advanced melanoma
$391,361Wei Li · University Of Tennessee Health Sci Ctr · R01 · FY2016 · CA
Monoclonal antibodies to inhibit Aspergillus germination
$391,357Marta L. Feldmesser · Albert Einstein College Of Medicine · R01 · FY2010 · AI
Combinatorial beta Cell-Specific Cytokine Therapy to Reverse Type I Diabetes
$391,354Roland Michael Tisch · Univ Of North Carolina Chapel Hill · R01 · FY2015 · DK
Advanced Rigidity-based Material for Enhanced Immunotherapy
$391,353Lance C Kam · Columbia University Health Sciences · R01 · FY2016 · AI
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2
$391,317Dai Fukumura · Massachusetts General Hospital · R01 · FY2024 · NS
DEVELOPMENT & EVALUATION OF PRACTICABLE APPROACHES FOR GENERATION OF CYTOTOXIC &
$391,307Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2010 · CA
MEMORY T CELLS IN EAE
$391,304Samia J. Khoury · Brigham And Women'S Hospital · R01 · FY2010 · AI